Revolution Medicines (RVMD) Liabilities and Shareholders Equity (2019 - 2026)

Revolution Medicines' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $2.3 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 4.72% year-over-year to $2.3 billion; the TTM figure through Mar 2026 stood at $9.3 billion (up 9.35% YoY), while the FY2025 annual figure was $2.4 billion, down 7.97% from the prior year.
• Liabilities and Shareholders Equity was $2.3 billion for Q1 2026 at Revolution Medicines, down from $2.4 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.6 billion in Q4 2024 to a low of $632.8 million in Q2 2022.
• Historically, Liabilities and Shareholders Equity has averaged $1.6 billion across 5 years, with a median of $1.8 billion in 2024.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity fell 18.25% in 2022, then soared 153.93% in 2023.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $811.9 million in 2022, then jumped by 153.93% to $2.1 billion in 2023, then climbed by 24.09% to $2.6 billion in 2024, then decreased by 7.97% to $2.4 billion in 2025, then dropped by 4.28% to $2.3 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $2.3 billion (Q1 2026), $2.4 billion (Q4 2025), and $2.3 billion (Q3 2025), per Business Quant data.